Quote this publication Share Print

EXELON

-
Opinions on drugs - Posted on Aug 01 2008

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication of “Symptomatic Treatment of Mild to Moderately Severe Forms of Dementia in Patients with Idiopathic Parkinson’s Disease.”

-


Actual benefit

Modéré

The actual benefit achieved with this proprietary medicinal product in this indication is moderate.


Improvement in actual benefit

IV (mineur)

Given the modest benefit observed and the risk of by no means negligible adverse reactions, Exelon provides a minor improvement in actual benefit (IAB IV) to patients with mild to moderately severe dementia associated with idiopathic Parkinson’s disease. The Commission notes that patients with visual hallucinations may particularly benefit from rivastigmine.


Contact Us

Évaluation des médicaments
All our publication